Supplementary Table S3 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase Ii Nrg-Gy023 Trial

AuthID
 P-019-2YV
20
Author(s)
Lee, J
·
Miller, A
·
Rose, PG
·
AlHilli, M
·
Washington, C
·
John, VS
·
Shah, CA
·
Matsuo, K
·
Siedel, J
·
Hopp, EE
·
O’Shea, A
·
Chan, JK
·
Bradford, LS
·
Morse, CB
·
Nagel, CI
·
Rodabaugh, KJ
·
Kohn, EC
·
Moore, KN
·
Liu, JF
Document Type
Unpublished
Year published
2025
Published
Indexing
Crossref®
Google Scholar®
Publication Identifiers
Export Publication Metadata
Marked List
 Add to Marked List
Info
At this moment we don't have any links to full text documens.

footer slogan

Useful Links

Get Help

© 2025 CRACS & Inesc TEC - All Rights Reserved Privacy Policy | Terms of Service